Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
WALTHAM, Mass., June 26, 2018 — Fresenius Medical Care North America (FMCNA), the leading provider of kidney care products and services, today announced the publication of its 2018 Annual Medical Report, offering expert insights on the latest science and innovation that is transforming clinical practice and patient care. Entitled “Go Further, Faster: Translating Science Into Practice,” this year’s report features insights from more than two dozen FMCNA and Fresenius Medical Care leaders, researchers, scientists, mathematicians and caregivers from across the enterprise. The collective content demonstrates the power of uniting people and possibility toward one unified purpose: our patients.
In an introductory whitepaper, Frank Maddux, MD, FACP, FMCNA’s Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs, offers a visionary look into four key concepts shaping the evolution of kidney care:
“Our unmatched ability to translate science into practice and Fresenius Medical Care’s vertically-integrated structure ensures we always consider the clinical, behavioral and environmental factors impacting our patients’ lives,” said Dr. Maddux. “Embracing new science and innovation for the benefit of our patients is one of the many ways we are working to reimagine kidney care. This year’s annual medical report reflects the depth of our expertise and demonstrates our commitment to setting the industry standard for patient-centered care.”
Additional highlights from the report include:
Business units represented in the 2018 Annual Medical Report include FMCNA (Corporate); Fresenius Kidney Care; FreseniusRx; Fresenius Health Partners; Renal Therapies Group; Azura Vascular Care; Frenova Renal Research; Renal Research Institute and Acumen Physician Solutions.
Read the full report here.
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, Fresenius Medical Care North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.